504433-24-3 Usage
General Description
GW441756 hydrochloride is a potent and selective antagonist of the TRPV1 receptor, which plays a key role in pain sensation and inflammation. By blocking the TRPV1 receptor, GW441756 hydrochloride can effectively reduce pain and inflammation in various conditions, making it a promising candidate for the development of new analgesic and anti-inflammatory drugs. Additionally, GW441756 hydrochloride has been shown to have potential therapeutic applications in the treatment of chronic pain, neuropathic pain, and inflammatory diseases. Its unique mechanism of action and high selectivity make it a valuable tool for researchers studying the TRPV1 receptor and its role in pain and inflammation pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 504433-24-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,4,4,3 and 3 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 504433-24:
(8*5)+(7*0)+(6*4)+(5*4)+(4*3)+(3*3)+(2*2)+(1*4)=113
113 % 10 = 3
So 504433-24-3 is a valid CAS Registry Number.
504433-24-3Relevant articles and documents
Tandem Horner-Wadsworth-Emmons/Heck procedures for the preparation of 3-alkenyl-oxindoles: The synthesis of Semaxanib and GW441756
Lubkoll, Jana,Millemaggi, Alessia,Perry, Alexis,Taylor, Richard J.K.
experimental part, p. 6606 - 6612 (2010/10/19)
A tandem sequence involving Horner-Wadsworth-Emmons (HWE) olefination followed by a palladium-catalysed intramolecular Heck reaction has been developed to provide rapid access to 3-alkenyl-oxindoles from α-halo-anilides. This one-pot microwave accelerated process proceeds with catalytic palladium(II) acetate or tetrakis(triphenylphosphine)palladium, and has been used to prepare a range of adducts derived from aromatic, heteroaromatic and aliphatic aldehydes. The procedures can be used to prepare N-unprotected oxindoles directly and the applicability of the process has been established by carrying out one-pot syntheses of Semaxanib, an angiogenesis signalling inhibitor, and GW441756, an aza-oxindole Trk A inhibitor.
